Search

Peter F Lebowitz

from Villanova, PA
Age ~56
Get Report
Also known as:
Peter S Lebowitz, Peter L Lebowitz, Peter Lebowitz Fisher, Peter R
Related to:
Ida Lebowitz
Connected to:
Allen G Lebowitz, 92Barbara M Lebowitz, 72Clifford S Lebowitz, 76Laurie E Lebowitz, 61Lila J Lebowitz, 73Mark Lebowitz, 70Phil L Lebowitz, 72Sally E Lebowitz, 89David A Leboy, 56Takie S Lebra, 95

Peter Lebowitz Phones & Addresses

  • Villanova, PA
  • Wayne, PA
  • 269 Hathaway Cir, Wynnewood, PA 19096 (610) 642-4072
  • 40 Meeting House Rd, Greenwich, CT 06831 (203) 661-2852
  • 3229 Idaho Ave, Wash, DC 20016 (202) 237-7043
  • 2431 39Th St, Washington, DC 20007 (202) 338-4466
  • Durham, NC
  • Philadelphia, PA
  • Montgomery, PA
  • 3229 Idaho Ave NW, Washington, DC 20016 (202) 841-2006

Work

Company: Janssen, pharmaceutical companies of johnson and johnson Jul 2012 Position: Global oncology therapeutic area head, svp

Education

School / High School: Perelman School of Medicine University of Pennsylvania 1996

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 2002

Industries

Pharmaceuticals

Specialities

Oncology • Medical Oncology

Professional Records

Medicine Doctors

Peter Lebowitz Photo 1

Dr. Peter Lebowitz, Wynnewood PA - MD (Doctor of Medicine)

View page
Specialties:
Oncology
Medical Oncology
Address:
269 Hathaway Ln, Wynnewood, PA 19096
Certifications:
Internal Medicine, 2002
Medical Oncology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1996
Peter Lebowitz Photo 2

Peter F Lebowitz

View page
Specialties:
Internal Medicine
Hematology & Oncology
Peter Lebowitz Photo 3

Peter Fisher Lebowitz, Washington DC

View page
Specialties:
Internist
Address:
3800 Reservoir Rd Nw, Washington, DC 20007

Resumes

Resumes

Peter Lebowitz Photo 4

Svp, Global Oncology Therapeutic Area Head At Janssen, Pharmaceutical Companies Of Johnson And Johnson

View page
Position:
Global Oncology Therapeutic Area Head, SVP at Janssen, Pharmaceutical Companies of Johnson and Johnson
Location:
Greater Philadelphia Area
Industry:
Pharmaceuticals
Work:
Janssen, Pharmaceutical Companies of Johnson and Johnson since Jul 2012
Global Oncology Therapeutic Area Head, SVP
Janssen, Pharmaceutical Companies of Johnson and Johnson - Radnor, PA 2011 - Jul 2012
Vice President and Head of Hematologic Malignancy Drug Discovery and Development
GlaxoSmithKline 2005 - 2011
Vice President and Head of Signal Transduction Drug Discovery/Development
GlaxoSmithKline 2005 - 2011
Vice President and Head of Oncology Early Clinical Development
Education:
Harvard University
Bachelor of Science (BS), Chemistry University of Pennsylvania
MD, PhD, Biochemistry and Molecular Biology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Peter F. Lebowitz
Peter Lebowitz MD
Internist
209 S Aberdeen Ave, Wayne, PA 19087
(610) 731-6021

Publications

Isbn (Books And Publications)

Hematology-oncology Therapy

View page
Author

Peter F. Lebowitz

ISBN #

0071434976

Us Patents

Methods Of Treating Cancer

View page
US Patent:
20130231346, Sep 5, 2013
Filed:
Nov 17, 2011
Appl. No.:
13/988054
Inventors:
Tona M. Gilmer - Research Triangle Park PA, US
Peter F. Lebowitz - Radnor PA, US
Li Liu - Collegeville PA, US
Jolly Mazumdar - Collegeville PA, US
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED - Middlesex
International Classification:
A61K 31/519
A61K 31/415
A61K 45/06
A61K 31/501
A61K 31/439
US Classification:
51425204, 5142641, 514291
Abstract:
Methods for treating a human with cancer comprise administering a therapeutically effective amount of at least one MEK inhibitor and at least one mTOR inhibitor to said patient, wherein said patient has at least one mutation in at least one Ras protein or gene encoding at least one Ras protein and/or wherein said patient has at least one mutation, deletion or insertion in LKB1/STK11.

Pharmaceutical Combination Of Mek Inhibitor And B-Raf Inhibitors

View page
US Patent:
20120196879, Aug 2, 2012
Filed:
Oct 15, 2010
Appl. No.:
13/499779
Inventors:
Melissa Dumble - Collegeville PA, US
Rakesh Kumar - Durham NC, US
Sylvie Laquerre - Collegeville PA, US
Peter Lebowitz - Collegeville PA, US
International Classification:
A61K 31/519
A61P 35/02
A61P 35/00
US Classification:
5142641
Abstract:
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.

Method Of Treating Cancer With Megea3 Immunotherapeutic With Braf Inhibitor And/Or Mek Inhibitor

View page
US Patent:
20150147350, May 28, 2015
Filed:
Dec 19, 2012
Appl. No.:
14/364770
Inventors:
- Wilmington DE, US
Sylvie Laquerre - King of Prussia PA, US
Peter F. Lebowitz - King of Prussia PA, US
Frederic Francois Eugene Lehmann - Rixensart, BE
Jamila Louahed - Rixensart, BE
International Classification:
A61K 39/00
A61K 31/506
A61K 31/519
A61K 38/16
US Classification:
4241921
Abstract:
A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and/or a MEK inhibitor, particularly N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.

Pharmaceutical Combination Of Mek Inhibitor And B-Raf Inhibitors

View page
US Patent:
20150111904, Apr 23, 2015
Filed:
Dec 22, 2014
Appl. No.:
14/578804
Inventors:
- Wilmington DE, US
Rakesh Kumar - Collegeville PA, US
Sylvie Laquerre - Collegeville PA, US
Peter Lebowitz - Collegeville PA, US
International Classification:
A61K 31/519
A61K 31/506
US Classification:
5142641
Abstract:
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. melanoma.

Pharmaceutical Combination Of Mek Inhibitor And B-Raf Inhibitors

View page
US Patent:
20140187566, Jul 3, 2014
Filed:
Mar 5, 2014
Appl. No.:
14/197421
Inventors:
- Philadelphia PA, US
Rakesh Kumar - Collegeville PA, US
Sylvie Laquerre - Collegeville PA, US
Peter Lebowitz - Collegeville PA, US
Assignee:
GlaxoSmithKline LLC - Philadelphia PA
International Classification:
A61K 31/519
A61K 31/506
US Classification:
5142641
Abstract:
A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Control profile
Peter F Lebowitz from Villanova, PA, age ~56 Get Report